Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
polycythemia vera | — | D011087 | D45 |
primary myelofibrosis | — | D055728 | D47.4 |
Expiration | Code | ||
---|---|---|---|
RUXOLITINIB PHOSPHATE, JAKAFI, INCYTE CORP | |||
2029-03-22 | PED | ||
2028-09-22 | ODE-373 | ||
2026-11-24 | PED | ||
2026-06-19 | PED | ||
2026-05-24 | ODE-238 | ||
2025-12-19 | M-285 | ||
2025-03-22 | PED | ||
2024-09-22 | I-872 | ||
RUXOLITINIB PHOSPHATE, OPZELURA, INCYTE CORP | |||
2026-01-18 | PED | ||
2025-07-18 | I-896 | ||
2025-03-21 | PED | ||
2024-09-21 | NP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Ruxolitinib Phosphate, Opzelura, Incyte Corp | |||
11602536 | 2041-05-05 | U-3550 | |
11510923 | 2040-09-04 | U-3505 | |
11590137 | 2040-09-04 | U-3505 | |
11590138 | 2040-06-10 | U-3551 | |
10758543 | 2031-05-20 | DP | |
10869870 | 2031-05-20 | U-3229, U-3404 | |
11219624 | 2031-05-20 | DP | U-3229 |
11571425 | 2031-05-20 | DP | |
11590136 | 2031-05-20 | U-3229, U-3404 | |
10610530 | 2028-06-12 | U-3229, U-3404 | |
9974790 | 2026-12-12 | U-3229, U-3404 | |
10639310 | 2026-12-12 | U-3229 | |
Ruxolitinib Phosphate, Jakafi, Incyte Corp | |||
8722693 | 2028-06-12 | DS, DP | |
8822481 | 2028-06-12 | U-1573, U-3226, U-3227, U-3228, U-3229, U-3230, U-3404 | |
8829013 | 2028-06-12 | U-1201, U-1622, U-3227, U-3228 | |
10016429 | 2028-06-12 | U-3226, U-3230 | |
7598257 | 2027-12-24 | DS, DP | U-3227, U-3228 |
8415362 | 2027-12-24 | DS, DP | |
9079912 | 2026-12-12 | U-3226, U-3227, U-3228, U-3229, U-3230, U-3404 | |
9814722 | 2026-12-12 | U-3226, U-3230 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Polycythemia | D011086 | EFO_0005804 | D75.1 | 3 | 5 | 6 | 2 | 6 | 21 |
Polycythemia vera | D011087 | — | D45 | 2 | 5 | 6 | 1 | 6 | 19 |
Primary myelofibrosis | D055728 | — | D47.4 | 6 | 7 | 4 | 2 | 2 | 19 |
Thrombocytosis | D013922 | — | D75.83 | 2 | 6 | 3 | 1 | 2 | 12 |
Essential thrombocythemia | D013920 | — | D47.3 | 2 | 6 | 3 | 1 | 1 | 11 |
Graft vs host disease | D006086 | — | D89.81 | 1 | 3 | 1 | 3 | 2 | 9 |
Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | 1 | — | 2 |
Thalassemia | D013789 | EFO_1001996 | D56 | — | 1 | — | 1 | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | 1 | 2 | 1 | — | 2 | 5 |
Cytokine release syndrome | D000080424 | — | D89.83 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 4 | 3 | — | — | — | 4 |
Lymphoid leukemia | D007945 | — | C91 | 4 | 3 | — | — | — | 4 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | 1 | — | — | — | 2 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | 1 | — | — | — | 2 |
Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | 1 | — | — | 1 | 2 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 2 | — | — | — | 2 |
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 1 | 1 | — | — | — | 1 |
Coronavirus | D017934 | — | — | 1 | 1 | — | — | — | 1 |
Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 1 | — | — | — | 1 |
Myeloid leukemia chronic-phase | D015466 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Philadelphia chromosome | D010677 | — | — | 1 | — | — | — | — | 1 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thromboembolism | D013923 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Ruxolitinib |
INN | ruxolitinib |
Description | Ruxolitinib is a pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. It has a role as an antineoplastic agent and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a nitrile, a pyrrolopyrimidine and a member of pyrazoles. |
Classification | Small molecule |
Drug class | deuterated compounds; tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1 |
PDB | — |
CAS-ID | 941678-49-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1789941 |
ChEBI ID | 66919 |
PubChem CID | 25126798 |
DrugBank | DB08877 |
UNII ID | 82S8X8XX8H (ChemIDplus, GSRS) |